Episodes

  • FDA's 2026 AI Device Scrutiny: Lifecycle Governance and Real-World Performance

    FDA's 2026 AI Device Scrutiny: Lifecycle Governance and Real-World Performance
    Mar 24 2026
    This episode explores the FDA's expected regulatory landscape for AI-enabled medical devices in 2026. We discuss the critical shift from pre-market assessment to a total product lifecycle approach, focusing on the non-negotiable requirements for real-world performance monitoring and Predetermined Change Control Plans (PCCPs). Learn what will separate scalable, approvable medtech platforms from demo-grade algorithms that cannot withstand long-term regulatory scrutiny. - How will the FDA's definition of 'safe and effective' for AI devices change by 2026? - What is a Predetermined Change Control Plan (PCCP) and why will it be mandatory? - Why is real-world performance monitoring becoming more critical than initial pilot data? - What is 'algorithmic drift' and how must manufacturers plan to manage it? - How does clinical workflow integration impact the regulatory viability of an AI device? - What separates a sustainable medtech platform from a simple AI algorithm? - How can you build a lifecycle governance strategy that meets future FDA expectations? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI tools. From developing a regulatory strategy and compiling your technical dossier to acting as your local representative in over 30 markets, we cover the entire product lifecycle. Our technology-driven approach ensures efficiency and accuracy, helping you navigate complex requirements for market approval and post-market surveillance. To access new markets faster and ensure ongoing compliance, contact Pure Global at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show More Show Less
    3 mins
  • Home-Use Device Recalls & Firmware Updates: Navigating the MedTech Logistical Nightmare

    Home-Use Device Recalls & Firmware Updates: Navigating the MedTech Logistical Nightmare
    Mar 15 2026
    This episode delves into the top health technology hazard: the logistical challenges of communicating recalls and firmware updates for home-use medical devices. We explore the fragmented communication chain from manufacturer to patient, the difficulties in executing physical returns and software corrections for non-clinical users, and the regulatory definition of a firmware update as a recall. - Why are home-use device recalls considered the #1 medical tech hazard? - What makes communicating with patients so different from communicating with hospitals? - How does the fragmented supply chain prevent manufacturers from reaching end-users? - Are critical firmware or software updates considered a medical device recall by the FDA? - What were the key communication failures in the massive 2021 CPAP machine recall? - What are the logistical challenges of physically retrieving thousands of devices from patients' homes? - How can companies ensure non-technical users apply critical updates correctly? - What is the Unique Device Identification (UDI) system and how might it solve this problem? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access with local expertise and advanced AI. Our services cover the entire product lifecycle, from initial regulatory strategy and technical dossier submission to post-market surveillance and continuous regulatory monitoring. By acting as your local representative in over 30 markets, we ensure your products not only get to market but also maintain compliance in complex, ever-changing regulatory landscapes. Visit us at https://pureglobal.com, contact info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show More Show Less
    3 mins
  • Securing the MedTech Supply Chain: Blockchain vs. 3D-Printed Counterfeits

    Securing the MedTech Supply Chain: Blockchain vs. 3D-Printed Counterfeits
    Mar 14 2026
    The rise of sophisticated 3D-printed counterfeit medical devices presents a grave threat to patient safety and brand integrity. This episode delves into the escalating battle between counterfeiters and MedTech manufacturers, exploring the cutting-edge technologies being deployed to secure the global supply chain. We examine how solutions like blockchain and invisible marking technologies are becoming essential for verifying product authenticity, ensuring traceability, and complying with increasingly strict international regulations. Key Questions: - How has 3D printing revolutionized the counterfeit medical device industry? - What are the most significant risks counterfeit products pose to patients? - How does blockchain technology create a secure and traceable supply chain? - What are invisible markings, and how do they help verify a product's authenticity? - Why are these expensive technologies becoming a necessary investment for manufacturers? - How do anti-counterfeiting measures align with regulatory requirements like the FDA and EU UDI systems? - What is the impact of counterfeiting on a MedTech company's brand and market access? Navigating the complexities of global supply chain security and regulatory compliance is a significant challenge. Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging local expertise and advanced AI to streamline global market access. From developing regulatory strategies and managing technical submissions to ensuring post-market surveillance, Pure Global acts as your local representative in over 30 markets. Our technology-driven approach ensures efficiency and accuracy in securing your product's journey to market. Visit https://pureglobal.com/, contact us at info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai to accelerate your expansion.
    Show More Show Less
    3 mins
  • Self-Healing Logistics: Automating Medical Device Supply Chains in a Volatile World

    Self-Healing Logistics: Automating Medical Device Supply Chains in a Volatile World
    Mar 13 2026
    This episode explores the rise of "self-healing" supply chains, an AI-driven solution designed to combat the logistical nightmares caused by modern geopolitical tensions. We examine how these automated networks use predictive analytics to anticipate disruptions, autonomously reroute critical medical device shipments, and maintain regulatory compliance in a volatile world. This shift from reactive to proactive logistics is becoming a necessity for ensuring patient safety and building resilient MedTech operations. - What is a "self-healing" supply chain and why is it critical for MedTech now? - How do geopolitical tensions directly threaten the delivery of medical devices? - Can AI really predict a stockout before it happens? - How do automated logistics networks make decisions without human intervention? - What are the regulatory compliance challenges of an autonomous supply chain? - How does this technology ensure patient safety during a global crisis? - What data sources fuel these predictive AI models? - How is Unique Device Identification (UDI) managed in a dynamic supply network? Facing complex global supply chains and regulatory hurdles? Pure Global offers end-to-end consulting for MedTech and IVD companies, leveraging advanced AI and a network of local experts in over 30 markets. We develop efficient regulatory strategies, manage technical submissions, and provide continuous monitoring to ensure your products stay compliant. Our technology-driven approach streamlines global market access, helping you navigate volatility with confidence. Let us be your partner in building a resilient global presence. Visit us at https://pureglobal.com, contact info@pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show More Show Less
    3 mins
  • AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal

    AI Diagnostic Bias: Navigating FDA and Global Regulations to Avoid Market Withdrawal
    Mar 12 2026
    This episode explores the growing regulatory pressure on medical device manufacturers to mitigate algorithmic bias in AI-powered diagnostics. We discuss why "black box" algorithms are facing scrutiny, what bodies like the FDA are now requiring as evidence of equitable performance, and the significant risks of failing to address bias, including market withdrawal. - What is "algorithmic bias" in the context of AI medical devices? - Why are regulators demanding transparency in AI models? - What specific evidence must manufacturers provide to prove their AI performs equitably across diverse populations? - How has FDA guidance on AI bias evolved since 2021? - What are the financial and reputational risks of a biased diagnostic tool? - How can you integrate bias mitigation into your product's entire lifecycle? - What documentation is now essential for your technical file and marketing submission? - Can failure to address AI bias lead to a product recall? Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex challenges like AI bias. Our experts develop robust regulatory strategies and use advanced AI tools to efficiently compile technical dossiers that meet the stringent requirements of global authorities like the FDA and EU. We help you demonstrate equitable performance and secure market access for your innovative devices. Ensure your product is ready for global markets by contacting us at info@pureglobal.com or visiting https://pureglobal.com. Explore our free AI-powered regulatory tools and database at https://pureglobal.ai.
    Show More Show Less
    4 mins
  • ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift

    ASC Sales Strategy: Adapting MedTech for the 2026 Procedure Shift
    Mar 11 2026
    This episode explores the strategic pivot required for MedTech companies as over 500 surgical procedures shift to Ambulatory Surgery Centers (ASCs) by 2026. We break down why traditional hospital-focused sales models are failing in the high-efficiency ASC environment and outline the new logistics, pricing, and value propositions needed to succeed in this rapidly growing market. - Why is the 2026 procedural shift to ASCs a critical challenge for MedTech sales teams? - How do purchasing decisions in an ASC differ from those in a hospital? - What common mistakes do hospital-focused sales teams make when approaching ASCs? - What are the essential logistics and pricing models required for the ASC environment? - How can you tailor your value proposition to appeal directly to surgeon-owners? - Is your company prepared for the addition of over 500 procedures to the ASC-approved list? - What specific strategies will win in the competitive Ambulatory Surgery Center market? Pure Global offers end-to-end regulatory consulting to help MedTech companies capitalize on market shifts like the move to ASCs. Our experts develop efficient regulatory strategies and conduct market research to identify the best pathways for expansion. By combining local expertise in over 30 markets with advanced AI tools, we streamline the process of getting your product approved and ready for sale. Whether you're a startup or a multinational, we help you navigate complex environments and optimize your product portfolio for new opportunities. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.
    Show More Show Less
    3 mins
  • MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures

    MedTech's Subscription Shift: Surviving the Death of Hospital Capital Expenditures
    Mar 10 2026
    This episode explores the pivotal shift in hospital procurement from traditional capital expenditures (CapEx) to subscription-based Device-as-a-Service (DaaS) models. We analyze why this change is occurring and detail its disruptive impact on medical device manufacturers, covering critical adjustments required in revenue recognition, sales compensation, customer relationships, and even product design to thrive in this new service-oriented landscape. Key Questions - Why are hospitals moving away from large, upfront equipment purchases? - What is included in a "Device-as-a-Service" (DaaS) contract? - How does subscription billing fundamentally change revenue recognition for MedTech companies? - What new sales commission structures are needed for a recurring revenue model? - How does the manufacturer-customer relationship evolve from transactional to a long-term partnership? - What are the implications for product design and durability in a DaaS model? - Can subscription models create a competitive advantage in new international markets? Navigating disruptive commercial models requires a forward-thinking global strategy. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you develop efficient pathways for market access and identify the best countries for expansion. Our unique combination of local expertise and advanced AI tools streamlines the creation of technical dossiers and keeps you ahead of regulatory changes. Let us help you turn market shifts into opportunities. Contact Pure Global at info@pureglobal.com, visit us at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.
    Show More Show Less
    3 mins
  • USA's Breakthrough Device Dilemma: Closing the Medicare Reimbursement Gap

    USA's Breakthrough Device Dilemma: Closing the Medicare Reimbursement Gap
    Mar 9 2026
    This episode delves into the critical reimbursement gap facing innovative medical devices in the United States. We explore why FDA Breakthrough Device designation doesn't guarantee Medicare payment, the financial "valley of death" this creates for MedTech startups, and how the proposed "Ensuring Patient Access to Critical Breakthrough Products Act" aims to provide a vital four-year bridge of temporary coverage. - What is the FDA's Breakthrough Devices Program? - Why does FDA approval not automatically lead to Medicare reimbursement? - What is the "reimbursement valley of death" for MedTech innovators? - How does the evidence required by the FDA differ from that required by CMS? - What was the MCIT rule and why was its 2021 repeal significant? - What is the "Ensuring Patient Access to Critical Breakthrough Products Act"? - How does the proposed four-year transitional coverage period work? - Why is this legislation critical for medical innovation and patient access? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient pathways for regulatory approval, leveraging advanced AI to compile and submit technical dossiers that minimize rejections. Our experts act as your local representative in over 30 markets, helping you identify the best regions for expansion and ensuring your innovative products reach patients faster. Whether you are a startup or a multinational enterprise, our technology-driven solutions are tailored to your needs. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our FREE AI tools at https://pureglobal.ai.
    Show More Show Less
    3 mins